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it may be possible to determine whether a perceptual mecha
nism might contribute to or trigger FOG.
Thus, the aim of this experiment was to evaluate the effect of
doorway size on gait before reaching the doorway in two groups
of individuals with Parkinson’s disease: (1) those who experience
freezing of gait (Parkinson’s disease FOG) and (2) those who
experience gait abnormalities but are absent of FOG (Parkinson’s
disease Non FOG).
SUBJECTS AND METHODS
Participants
The study involved 31 participants with Parkinson’s disease
(15i conﬁrmed to be experiencing FOG at the time of test, 16
absent of FOG) and 16 healthy, age matched control
participants (no signiﬁcant differences for age, height or
symptom severity between groups; for full details of participant
characteristics, see table 1) recruited from a database at the
Movement Disorders Research and Rehabilitation Centre at
Wilfrid Laurier University in Waterloo, Canada. In this database,
participants in the Parkinson’s disease FOG group were selected
based on their self report of experiencing freezing. Initially,
patients would be interviewed by a trained clinician (about their
experience of freezing) but only if they had scored a 1 or higher
on question 14 of the Uniﬁed Parkinson’s Disease Rating Scale
(UPRS). This question speciﬁcally addresses whether or not
freezing was experienced by the participant at the time they
enrolled as a research centre participant. Additionally, a trained
clinician conﬁrmed the occurrence of freezing in these patients
at the time of the test (see the Procedures subsection below).
All patients who were tested had clinically typical Parkinson’s
disease as conﬁrmed by diagnosis from at least one movement
disorder neurologist and were known to be responsive to anti
parkinsonian medication. All participants with Parkinson’s
disease were tested approximately 1 h after having taken their
anti Parkinson’s medication. However, criteria were used to
verify that individuals in the FOG group were experiencing
episodes of freezing at the time of the test (see the Procedures
subsection below). Participants in the non FOG Parkinson’s
disease group scored at least a 1 (out of 4) on the gait portion of
the UPDRS Motor section III by a movement disorder specialist
and had no self reported incidents of freezing in their case
history. Sixteen healthy control individuals also participated in
the study. These individuals were mostly spouses or relatives of
the participants with Parkinson’s disease.
Participants were excluded from testing if they had a history
of neurological conditions other than Parkinson’s disease, or
orthopaedic or visual disturbances that severely impaired
walking ability. Participants were also excluded if they had been
previously diagnosed by a neurologist with dementia, had
a conﬁrmed score of <27 on the Mini Mental State Examina
tion, or had dyskinesias, which would alter their gait pattern.
Each participant was informed about the requirements of the
study and signed institutionally approved consents, according to
the declaration of Helsinki (BMJ 1991; 302: 1194).
Materials
The room used for data collection was a laboratory containing
a metal framed double doorway leading into an empty hallway.
The double doorway acted as the wide doorway condition (ie,
two times normal door width), whereas the single doorway was
used for the normal doorway condition. A perfectly colour
matched wooden plank was ﬁtted in to the side of the single
doorway for the narrow doorway condition. The lighting in the
laboratory and the hallway was maintained at a consistent
brightness. Data were collected on a GAITRite carpet
(GAITRite, CIR System, Inc., Clifton, New Jersey, USA), which
is 3.96 m long 3 0.79 m wide and contains sensors that send
information received from the participants’ footsteps to an
attached computer. A researcher walked alongside (and slightly
behind) the participant at all times for safety of the participant
during each trial.
Procedure
Pretest procedure
In addition to the UPDRS assessment of gait (used to conﬁrm
the presence of freezing), an additional measure was developed
to further establish the experience of freezing at the time of the
test. Each participant in the Parkinson’s disease FOG group
performed a modiﬁed version (through a doorway) of the timed
up and go test (TUG). This test began with the patients seated
in a chair and, upon a go signal, they proceeded to stand and
walk through a doorway to a marker on the ground located 3 m
from the chair. Once they reached this marker, they turned and
proceeded back to the chair to sit down. This was observed by
a movement disorder specialist who conﬁrmed that the partic
ipant was experiencing a sudden inability to initiate or continue
walking at some point during the TUG before continuing to the
normal testing procedure. If FOG indicators were absent, the
patient was excluded from testing.
Test procedure
Participants walked the length of the GAITRite carpet that was
positioned so that participants would walk through a doorway,
in three randomised conditions that were ﬁve (blocked) trials
each. Each trial commenced with the participant, with eyes
closed, standing 2 m before the start of a GAITRite carpet. This
ensured that characteristics of gait initiation were not recorded.
Participants were instructed to start walking as soon as they
opened their eyes, and walk the length of the GAITRite carpet
through the doorway. The three experimental conditions were:
1. Narrow doorway condition in which the participant walked
through a smaller than normal (3/4 size) doorway (0.675 m
wide 3 2.1 m high). The wooden plank designed to make the
doorway narrow partially overlapped the GAITRite carpet in
this condition.
2. The normal doorway condition acted as the baseline control
condition in which the participant walked through a normal
sized doorway (0.9 m wide 3 2.1 m high).
Table 1 Characteristics of the three groups
Group
Age M
(yrs) Height M (cm)
UPDRS M
(score)
Years since
diagnosis M (yrs) Dose of levodopa M (mg) Sex
Parkinson’s disease FOG 72.4 (6.79) 172.51 (8.51) 32.8 (7.34) 9.07 (5.29) 1013.33 (390.27) 13 male, 2 female
Parkinson’s disease Non FOG 72.19 (6.23) 170.66 (9.69) 28.81 (6.35) 5.97 (4.61) 725.0 (449.81) 10 male, 6 female
HC 70.75 (5.98) 167.96 (7.53) NA NA NA 6 male, 10 female
M, mean.
Initially, 20 Parkinson’s disease patients who had self reported freezing were recruited for the study. Based on the described screening protocol employed to confirm freezing at the time of test,
five patients were excluded and are not reported in the current data set.
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3. Wide doorway condition in which the participant walked
through a double sized doorway (1.8 m wide 3 2.1 m high).
The three conditions in this protocol allowed for the analysis
of whether the size of doorway is a contributing factor to the
gait alterations and FOG experienced while travelling through
conﬁned spaces. Only data of the spatiotemporal gait charac
teristics collected prior to the doorway were included for anal
ysis. This allowed for the analysis of anywhere from four to
seven steps depending on the participants’ step length. Any foot
falls at or after the doorway were excluded from analysis in this
experiment.
Statistical analysis
There were three independent groups in this experiment: indi
viduals with Parkinson’s disease experiencing FOG (Parkinson’s
disease FOG), those with Parkinson’s disease experiencing gait
abnormalities absent of FOG (Parkinson’s disease non FOG) and
healthy control individuals (Controls). As suggested by Morris et
al,27 individuals with Parkinson’s disease are known to have
deﬁcits in velocity, step length, step timing and base of support.
As such, the primary dependent variables analysed were gait
velocity (cm/s), mean step length (cm), which is equal to the
length of a toe off to the opposite foot heel contact, base of
support (cm), cadence (steps/min), time spent in double support
(s). In addition, Hausdorff et al,10 have supported the evaluation
of step to step variability as a precursor of FOG. Hence, two
measures of step to step variability were calculated for each of
the spatiotemporal measures: (1) within trial SD around each
individual participant’s mean value for a trial was averaged
across participants in a given group, and (2) the coefﬁcient of
variation (CV) within a trial was calculated based on SD (see
(1)) divided by the average value for a given trial in order to
account for variability normalised to the mean. Left and right
steps were pooled and the results were analysed by the
STATISTICA computerised statistical package using a mixed
model of three groups3 three conditions 3 ﬁve trials analysis of
variance (ANOVA). In order to determine where the signiﬁcant
differences found in the ANOVAs occurred, Tukey’s Honest
Signiﬁcant Difference (HSD) post hoc procedure was employed.
Role of the funding source
The funding source behind this research did not have any
involvement in the study design; in the collection, analysis and
interpretation of data; in the writing of the report; nor in the
decision to submit the paper for publication.
RESULTS
Participant demographics
To determine whether signiﬁcant differences existed between
the three groups, an ANOVA was performed and found no
signiﬁcant differences between the groups age and height. A t
test was also performed and found no signiﬁcant differences
between the Parkinson’s disease FOG and Parkinson’s disease
non FOG group in regards to their years since diagnosis or the
amount of levodopa they were taking. There was also no
signiﬁcant difference found with regards to disease progression
as indicated by their UDPRS score.
Gait velocity
Individuals who experience FOGwere found towalk signiﬁcantly
slower (85.5 (30.0) cm/s) on average as compared with the
Parkinson’s disease non FOG group (107.3 (18.8) cm/s) and the
Control group (119.3 (12.81) cm/s), as demonstrated by a main
effect of group (F(2,44)¼10.90, p<0.001). Post hoc analysis
conﬁrmed that the Parkinson’s disease FOG group walked at
a signiﬁcantly slower velocity as compared with the Parkinson’s
disease non FOG group (20.3% decrease, p¼0.012) and the
Control group (28.3 % decrease, p<0.001). There was no
signiﬁcant interaction of velocity observed with condition.
An interaction was identiﬁed between group and trial
(F(8, 176)¼2.36, p<0.0195). This interaction demonstrated that
the Parkinson’s disease FOG group was the only group to expe
rience a reduced velocity in their ﬁrst encounter with the
doorway. Neither the Parkinson’s disease non FOG group nor the
Healthy Control group altered their velocity through the trials.
Step length
It was also observed that the Parkinson’s disease FOG group had
a signiﬁcantly smaller step length (45.9 (13.9) cm) as compared
with the Parkinson’s disease non FOG group (56.6 (7.4) cm) and
the Control group (63.9 (6.8) cm). This was evident from the
observed main effect of the group (F(2, 44)¼13.11, p<0.001). Post
hoc analysis conﬁrmed that the Parkinson’s disease FOG group
had a signiﬁcantly smaller step length than the Parkinson’s
disease non FOG group (p<0.011) and the Control group
(p<0.001). The Parkinson’s disease non FOG group did not differ
signiﬁcantly from the Control group.
More importantly, a signiﬁcant interaction of step length was
found when comparing group and condition (F(4,88)¼2.73,
p<0.034) (ﬁgure 1). The narrow doorway signiﬁcantly decreased
the step length of the Parkinson’s disease FOG group, while the
other two groups were not affected. This was conﬁrmed
through post hoc analysis in which the narrow doorway caused
the Parkinson’s disease FOG group to shorten their steps (42.5
(15.4) cm) as compared with the normal doorway (46.4
(13.9) cm) by 8.4% (p<0.005) and wide doorway (48.7
(13.5) cm) by 12.7% (p<0.001).
An interaction was identiﬁed between the group and the trial
when examining step length (F(8, 176)¼6.08, p<0.001). The
Parkinson’s disease FOG group demonstrated a signiﬁcantly
smaller step length in their ﬁrst encounter with the doorway
(43.4 (15.5) cm) as compared with the other trials (p<0.029).
Neither the Parkinson’s disease non FOG nor the Control group
altered their step length with respect to trial.
Base of support
A signiﬁcant interaction of group and condition was found
when analysing base of support (F(4, 88)¼3.96, p<0.053)
(ﬁgure 2). Base of support did not signiﬁcantly change with
Figure 1 Changes in step length over the three conditions in the
Parkinson’s disease FOG group, Parkinson’s disease non-FOG group and
controls.
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condition in either the Parkinson’s disease FOG group or the
Control group. Also, it was found that the Parkinson’s disease
FOG group had a signiﬁcantly larger base of support (on average,
29.6% larger) as compared with that of the Control group
(p<0.001) across all conditions. The Parkinson’s disease FOG
groups’ base of support was found to be consistently the widest
and the Control group the narrowest. In the wide doorway
condition, individuals in the Parkinson’s disease non FOG group
were found to behave like those of the Control group, with both
groups revealing a signiﬁcantly smaller base of support when
compared with the Parkinson’s disease FOG group (p<0.001). In
the normal doorway, the Parkinson’s disease non FOG group
differed from both groups, with a signiﬁcantly smaller base of
support than that of the Parkinson’s disease FOG group (p<
0.001) and a wider base of support than that of the Control
group (p<0.004). Interestingly, when confronted with the
narrow doorway condition, the Parkinson’s disease non FOG
group behaved similar to the Parkinson’s disease FOG group and
only differed from the Controls, who continued to display the
narrowest base of support (p<0.001). Solely, the Parkinson’s
disease non FOG group altered the size of their base of
support with respect to doorway as they exhibited a wider base
of support when approaching the narrow doorway
(19.6 (6.9) cm) as compared with the wide doorway (17.3
(7.7) cm, p<0.035).
Step length variability
When comparing groups for within trial step length variability,
a main effect was found (F(2, 44)¼7.79, p<0.002). Post hoc
analysis conﬁrmed that the Parkinson’s disease FOG group (2.9
(1.5) cm) had signiﬁcantly greater step length variability as
compared with the Parkinson’s disease non FOG group (1.6
(0.9) cm, p< 0.004) and the Controls (1.0 (0.5) cm, p< 0.001). A
signiﬁcant interaction was also identiﬁed between group and
condition (F(4, 88)¼2.99, p<0.023) (ﬁgure 3). The Parkinson’s
disease FOG group was the only group found to exhibit an
increased step length variability in the narrow (3.2 (1.8) cm,
p<0.001) doorway and the normal (3.0 (1.8) cm, p< 0.091)
doorway as compared to the wide (2.4 (1.2) cm,) doorway
condition. Neither the Parkinson’s disease non FOG group nor
the Control group demonstrated a change in step length vari
ability as a result of doorway condition.
In order to normalise against mean values, the CV of step
length was analysed, revealing a signiﬁcant group versus
condition interaction (F(4, 88)¼2.85, p<0.029) (ﬁgure 4). Solely,
the Parkinson’s disease FOG group was affected by the size of
doorway, as they experienced a higher CV with regards to step
length in the narrow doorway (0.118, (0.129)) as compared with
the wide doorway (0.06 (0.048), p<0.004).
Step duration
Without the data being normalised, there were no signiﬁcant
group, condition or trial effects with regards to step duration.
However, the CV of step duration was analysed and revealed
a main effect of group. The Parkinson’s disease FOG group was
found to have a signiﬁcantly higher CV (0.085 (0.088)) as
compared with the Parkinson’s disease non FOG group (0.031
(0.02), p< 0.015) and the Control group (0.018 (0.007), p<0.002)
groups (F(2, 44)¼7.45, p<0.002). Also, a trend reaching signiﬁ
cance was found between group and condition, indicating that
the participants in the Parkinson’s disease FOG group were the
only ones affected by doorway size (with respect to CV of step
duration).
DISCUSSION
The primary objective of the current study was to evaluate the
inﬂuence of space perception on gait in individuals with Parkin
son’s disease who experience FOG, other Parkinson’s disease
patients (absent of FOG) and healthy age matched participants.
Freezing is extremely difﬁcult to draw out in experimental
settings,28 as was also the case during the current experiment,
which has been suggested to be caused by a heightened attention
due to participation in an experiment.9 However, several studies
have shown decreased stride length and increased gait timing
variability before a freezing episode.10 Therefore, in spite of a lack
of actual freezing episodes, the obtained results demonstrate that
an upcoming conﬁned space has a profound effect on gait in
patients experiencing FOG. Overall, the gait of the FOG partici
pants was signiﬁcantly more variable when compared with the
Figure 2 Base of support alterations across condition.
Figure 3 Parkinson’s disease FOG group displays increased step
length variability in narrow condition.
Figure 4 Step length coefficient of variation over the three conditions
in the Parkinson’s disease FOG, Parkinson’s disease non-FOG and control
groups.
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other groups (as demonstrated byCVdata for step length and step
duration), which is in agreement with previous research demon
strating an increase in gait variability before a freeze.10 Perhaps
important to note is that these indicators of freezing are occurring
well before arrival at the actual doorway, suggesting that online
perceptual processes must be interrupting the initial movement
plan to pass through the doorway. Thus, impaired perceptual
ability may be an important factor contributing to freezing in
Parkinson’s disease.
This is the ﬁrst study to demonstrate that while approaching
a narrow doorway, freezers already exhibit alterations to gait
(shortened step length, increased gait variability, increased base
of support) that are indicative of an upcoming freezing episode.
These changes were not evident in non FOG individuals with
Parkinson’s disease, or healthy participants. In fact, non FOG
individuals showed a constant deﬁcit in step length (compared
with healthy ones), regardless of doorway size. Our results are in
direct contrast to Van Wegen et al who demonstrated that small
spaces presented in the form of a virtual corridor had no effect
on gait in Parkinson’s disease.28 A group by trial interaction
reafﬁrms that the Parkinson’s disease FOG group were most
affected (in terms of step length and velocity) upon their ﬁrst
encounter with the doorway, whereas the two other groups
were unaffected by trial. This may suggest that experience (ie,
practice) helps Parkinson’s disease patients improve their spatial
perception to conﬁrm a door size, although heightened anxiety
level (in a group of patients that are prone to falling) during the
ﬁrst encounter with the narrow cannot be ruled out. Therefore,
perceptual judgment of the upcoming doorway, and thus
a certain degree of visuospatial ability, appears to be more greatly
affected in Parkinson’s disease patients who experience freezing.
Base of support is generally considered to be a measure of
stability, and hence, we hypothesised that the Parkinson’s
disease FOG group might attempt to maximise stability by
increasing base of support in the narrow doorway condition.
However, the Parkinson’s disease FOG group showed a consis
tent increase in base of support that was not signiﬁcantly
inﬂuenced by doorway size. Since freezers are substantially more
unstable, they may adopt a wide base of support regardless of
environmental context. Interestingly, the Parkinson’s disease
non FOG group altered their base of support only in anticipation
of the narrow doorway (similar to freezers) and yet were not
affected by the other doorways. In contrast, healthy control
participants have a high level of stability and hence, maintained
a normal (and narrower) base of support regardless of condition
(compared with the Parkinson’s disease groups).
In accordance with Hausdorff et al,10 29 the current study
found increased within trial step length and step duration vari
ability in only the FOG group, and this was more profound in
the narrow doorway speciﬁcally. It should be noted that they
were the only group to demonstrate this effect, providing
additional support to the hypothesis that perceptual impair
ments primarily affect individuals with freezing. The increased
step length variability is indicative of an unstable gait pattern
that may be reﬂective of an attempt to voluntarily control gait,
possibly by increasing the sampling of proprioceptive feedback.16
Freezers were unable to maintain a normal stride and instead
more frequently altered their step length, potentially leading to
an increased risk of falling.30 As suggested by Iansek et al,31 the
fact that a decreased step length (accompanied by increased
variability) can be identiﬁed before the narrow doorway suggests
that attentional or perceptual mechanisms (ie, involved in
processing characteristics of the door) contribute to the occur
rence of a freezing episode.
Although perception was not directly evaluated, our work
has provided a glimpse of the impact that perceptual mecha
nisms may have on severe gait deﬁcits such as freezing.
Changes in step length, base of support and within trial step
length and step duration variability all support the notion that
patients with FOG alter their gait in response to how they
perceive environmental contexts. This may be important to
consider since the observed changes in gait can be predictive of
an upcoming freezing episode.10 12 Parkinson’s disease patients
without FOG were also found to be affected by narrow door
ways, suggesting that increased perceptual constraints may
lead to gait alterations even in non freezers. Individuals with
Parkinson’s disease appear to be unable to accurately evaluate
self motion in relation to upcoming obstacles.22 This may be an
important perceptual factor to consider for other situations
such as entering an elevator or any other situation in which
patients may be approaching conﬁned or crowded spaces. We
recognise that there are certain situations that elicit FOG (ie,
turning) that may not be related to perception. Suggestive
mechanisms for freezing during turning include asymmetrical
gait.32
As previously mentioned, freezing is extremely difﬁcult to
draw out in laboratory settings; thus, it is important to consider
whether patients categorised as non freezers may have had the
experience of FOG within their own home environment. In the
case of the current study, categorisation into the non FOG group
was conﬁrmed by a movement disorders trained clinician, in
addition to self report (of experience at home), UPDRS (Q. 14)
and our modiﬁed TUG test. While the possibility exists that the
non FOG patients might progress into FOG, it is unlikely that
they would be experiencing any sort of FOG at the present time.
Individuals with Parkinson’s disease were tested while on
dopaminergic medication, which is a potential limitation of this
study, although it is has been shown that freezing is poorly
affected by medication.17 Testing was conducted solely in the
“on” state of Parkinson’s disease in order to get a true under
standing of the perceptual mechanisms that may commonly
occur while patients are medicated (as in everyday situations).
Future studies might include the testing of individuals with
FOG while “off” medication in order to obtain a clearer under
standing of basal ganglia contribution to freezing. The use of an
eye tracking device in future research could be useful in order to
monitor participants gaze directions while approaching the
doorway. Future research also should focus on underlying
perceptual mechanisms that may be prevalent in FOG (and
more generally in Parkinson’s disease) in order to better under
stand the causes of freezing. Taking these perceptual mecha
nisms into consideration will be important for the development
of effective treatment strategies to combat freezing.
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